Effect analysis of entecavir and adefovir ester combined with lamivudine in treating HBeAg-positive chronic hepatitis B

Objective To compare the effect and safety of entecavir(ETV)and adefovir ester combined with lamivudine(ADV+ LAM)for HBeAg-positive chronic hepatitis B(CHB). Methods A total of 110 HBeAg-positive CHB patients were selected in General Hospital of Jinan Military Command from July 2012 to July 2015, and they were randomly divided into ETV group(50 cases)and ADV+ LAM group(60 cases). The HBV-DNA negative conversion ratio, HBeAg seroconversion rate, alanine aminotransferase(ALT)recovery rate and adverse event rate were observed 48 and 96 weeks after treatment. Results The HBV-DNA negative conversion ratio(ETV vs.ADV+ LAM: 48 weeks 20 vs.15, 96 weeks 35 vs.45)and ALT recovery rate(ETV vs.ADV+ LAM: 48 weeks 40 vs.44, 96 weeks 48 vs.56)of the two groups were both improved 48 and 96 weeks after treatment, but the difference was not statistically significant(P>0.05). The difference of the HBeAg seroconversion rate between the two groups was not statistically significant for the first 48 weeks(ETV vs.ADV+ LAM: 48 weeks 10 vs.8). As time went on, the HBeAg seroconversion rate of ETV group was higher than that of ADV+ LAM group(96 weeks 18 vs.9). Conclusion In the treatment of HBeAg-positive CHB patients using ETV and ADV+ LAM, the more remarkable effect of HBeAg seroconversion rate of ETV is correlated with the longer follow-up, and the drug is safer. Key words: Hepatitis B; HBeAg-positive; Entecavir; Adefovir ester